BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

Several companies are looking for therapeutic combinations that change how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. and Oryx GmbH & Co. KG , are investigating co-administering the therapies with...
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
BioCentury | Feb 10, 2014
Finance

A Japanese correction

A Japanese correction Japan's biotechs exhibited the high beta typical of the sector last week, falling more than five times as much as the country's broader markets, which themselves have been taking a beating. Nevertheless,...
BioCentury | Jan 6, 2014
Finance

2014 Financial Markets Preview: Hoping the pause is brief

Bankers and buysiders are not expecting a repeat performance of biotech's stellar 2013. But the two dozen who spoke with BioCentury say the capital markets are primed to open back up this month, albeit on...
BC Week In Review | Dec 9, 2013
Financial News

Oncolys BioPharma completes IPO

Oncolys BioPharma Inc. (Tokyo:4588), Tokyo, Japan   Business: Infectious, Cancer, Diagnostic   Date completed: 12/2/13   Type: IPO   Raised: ¥4.7 billion ($46.4 million)   Shares: 1.8 million   Price: ¥2,600   Shares after offering:...
BC Extra | Dec 7, 2013
Financial News

Oncolys jumps in trading debut

Oncolys BioPharma Inc. (Tokyo:4588) gained Y930 (36%) to Y3,530 in its first day of trading on Friday on the Tokyo Stock Exchange's Mothers. Earlier this week, the company raised Y4.7 billion ($47.3 million) in an...
BC Extra | Dec 4, 2013
Financial News

Oncolys raises $46.4 million in Japanese IPO

Oncolys BioPharma Inc. (Tokyo, Japan) raised Y4.7 billion ($47.3 million) through the sale of 1.8 million shares at Y2,600 on the Tokyo Stock Exchange's Mothers. The price -- at the top end of the company's...
BioCentury | Nov 18, 2013
Finance

Thanksgiving break

Rumors of the IPO window's death are greatly exaggerated. Despite a handful of postponed biotech IPOs in the last two weeks, three money managers contacted by BioCentury say the market is merely taking a holiday...
BC Week In Review | Nov 4, 2013
Financial News

Oncolys BioPharma Inc. financial update

Oncolys received approval to list its shares on the Tokyo Stock Exchange's market of the high-growth and emerging stocks (Mothers). The company, which could not be reached for details, is slated to being trading on...
BC Extra | Nov 1, 2013
Financial News

Oncolys planning Japanese IPO

Oncolys BioPharma Inc. (Tokyo, Japan) said it received approval to list its shares on the Tokyo Stock Exchange's market of high-growth and emerging stocks (Mothers). The company could not be reached for details. Oncolys' festinavir...
Items per page:
1 - 10 of 23
BioCentury | Feb 29, 2016
Product Development

Oncolytic duos and Dx

Several companies are looking for therapeutic combinations that change how oncolytic viruses interact with cancer cells. At least two companies, Oncolys BioPharma Inc. and Oryx GmbH & Co. KG , are investigating co-administering the therapies with...
BioCentury | Feb 29, 2016
Product Development

Infectious enthusiasm

After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint...
BioCentury | Feb 10, 2014
Finance

A Japanese correction

A Japanese correction Japan's biotechs exhibited the high beta typical of the sector last week, falling more than five times as much as the country's broader markets, which themselves have been taking a beating. Nevertheless,...
BioCentury | Jan 6, 2014
Finance

2014 Financial Markets Preview: Hoping the pause is brief

Bankers and buysiders are not expecting a repeat performance of biotech's stellar 2013. But the two dozen who spoke with BioCentury say the capital markets are primed to open back up this month, albeit on...
BC Week In Review | Dec 9, 2013
Financial News

Oncolys BioPharma completes IPO

Oncolys BioPharma Inc. (Tokyo:4588), Tokyo, Japan   Business: Infectious, Cancer, Diagnostic   Date completed: 12/2/13   Type: IPO   Raised: ¥4.7 billion ($46.4 million)   Shares: 1.8 million   Price: ¥2,600   Shares after offering:...
BC Extra | Dec 7, 2013
Financial News

Oncolys jumps in trading debut

Oncolys BioPharma Inc. (Tokyo:4588) gained Y930 (36%) to Y3,530 in its first day of trading on Friday on the Tokyo Stock Exchange's Mothers. Earlier this week, the company raised Y4.7 billion ($47.3 million) in an...
BC Extra | Dec 4, 2013
Financial News

Oncolys raises $46.4 million in Japanese IPO

Oncolys BioPharma Inc. (Tokyo, Japan) raised Y4.7 billion ($47.3 million) through the sale of 1.8 million shares at Y2,600 on the Tokyo Stock Exchange's Mothers. The price -- at the top end of the company's...
BioCentury | Nov 18, 2013
Finance

Thanksgiving break

Rumors of the IPO window's death are greatly exaggerated. Despite a handful of postponed biotech IPOs in the last two weeks, three money managers contacted by BioCentury say the market is merely taking a holiday...
BC Week In Review | Nov 4, 2013
Financial News

Oncolys BioPharma Inc. financial update

Oncolys received approval to list its shares on the Tokyo Stock Exchange's market of the high-growth and emerging stocks (Mothers). The company, which could not be reached for details, is slated to being trading on...
BC Extra | Nov 1, 2013
Financial News

Oncolys planning Japanese IPO

Oncolys BioPharma Inc. (Tokyo, Japan) said it received approval to list its shares on the Tokyo Stock Exchange's market of high-growth and emerging stocks (Mothers). The company could not be reached for details. Oncolys' festinavir...
Items per page:
1 - 10 of 23